MENU
+Compare
OVID
Stock ticker: NASDAQ
AS OF
Dec 18, 04:49 PM (EDT)
Price
$1.02
Change
-$0.04 (-3.77%)
Capitalization
75.27M

OVID Ovid Therapeutics Forecast, Technical & Fundamental Analysis

Provides medicines to children and adults with neurological disorders

Industry Biotechnology
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for OVID with price predictions
Dec 17, 2024

OVID in downward trend: 10-day moving average moved below 50-day moving average on November 21, 2024

The 10-day moving average for OVID crossed bearishly below the 50-day moving average on November 21, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on OVID as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for OVID turned negative on December 13, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .

OVID moved below its 50-day moving average on December 10, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

OVID broke above its upper Bollinger Band on November 11, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OVID's RSI Oscillator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 185 cases where OVID Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.987) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). OVID has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (119.048) is also within normal values, averaging (260.687).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

OVID is expected to report earnings to fall 15.70% to -16 cents per share on March 17

Ovid Therapeutics OVID Stock Earnings Reports
Q4'24
Est.
$-0.17
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.34
Q1'24
Beat
by $0.05
Q4'23
Est.
$-0.22
The last earnings report on November 12 showed earnings per share of -20 cents, beating the estimate of -20 cents. With 234.70K shares outstanding, the current market capitalization sits at 75.27M.
A.I. Advisor
published General Information

General Information

Provides medicines to children and adults with neurological disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
441 Ninth Avenue
Phone
+1 646 661-7661
Employees
40
Web
https://www.ovidrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RGP8.370.14
+1.64%
Resources Connection
PM126.040.10
+0.08%
Philip Morris International
SCOR6.94-0.02
-0.29%
comScore
THRM39.46-0.69
-1.72%
Gentherm
ALSN112.19-2.35
-2.05%
Allison Transmission Holdings

OVID and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with AVTE. These tickers have moved in lockstep 90% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then AVTE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
+0.95%
AVTE - OVID
90%
Closely correlated
N/A
SYRE - OVID
37%
Loosely correlated
+3.44%
NAUT - OVID
36%
Loosely correlated
-1.00%
TVTX - OVID
36%
Loosely correlated
-2.06%
NRIX - OVID
36%
Loosely correlated
+1.78%
More

Groups containing OVID

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
+0.95%
OVID
(2 stocks)
93%
Closely correlated
-2.38%